Application of Surface Enhanced Raman Spectroscopy in Early Diagnosis of Nervous System Diseases and Tumors

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000041563

Enrollment

Unknown

Registered

2020-12-29

Start date

2021-01-01

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Disease/Tumor

Interventions

Gold Standard:1. Chinese Parkinson's disease diagnostic criteria (2016 version), Alzheimer's disease diagnostic criteria. 2. Pathological biopsy.

Index test:Surface&#32

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Neurodegenerative diseases: such as Alzheimer's disease, Parkinson's disease; 2. Early and mid-stage cancer patients.

Exclusion criteria

Exclusion criteria: Hereditary neurological diseases.

Design outcomes

Primary

Measure	Time frame
Cerebrospinal fluid Raman spectroscopy;blood Raman spectroscopy;SEN, SPC, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactZeng Ting-Ting

Department of Laboratory Medicine, West China Hospital

zengtt80@163.com+86 18980686716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026